• Log In or Create Account
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
Advanced Search
Hit Me With Your Best Shot! Routine Immunizations for People With HIV - IAS-USA
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs

Hit Me With Your Best Shot! Routine Immunizations for People With HIV

Hit Me With Your Best Shot! Routine Immunizations for People With HIV

Hit Me With Your Best Shot! Routine Immunizations for People With HIV
Presenter: Melanie A. Thompson, MD

Slides

On-Demand Webcast

Podcast

iasusa · Hit Me With Your Best Shot! Routine Immunizations for People With HIV

Hit Me With Your Best Shot! Routine Immunizations for People With HIV - IAS-USA

131 Steuart St, Suite 500, San Francisco, CA 94105

Phone: (415) 544-9400 | info@iasusa.org

  • Home
  • Activities
  • Resources
  • About
  • Contact
  • Login
  • Careers
  • Donate
  • Website Policies
© 2026 International Antiviral Society–USA. All Rights Reserved.
  • CROI
  • Conference on Bacteriophages
  • RWHAP CLINICAL CONFERENCE
  • Podcasts
  • Slides
  • Question of the Week
  • Guidelines
  • Contact
  • CME Courses
    • HIV In-Person and Virtual Courses
    • Current On-Demand Courses
    • About Courses
  • CME Webinars
    • Upcoming Webinars
    • Current On-Demand Webinars
    • MATE Act CME
    • About Webinars
  • Dialogues
    • Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
    • On-Demand Dialogues
    • About Dialogues
  • Topics In Antiviral Medicine
    • Current Issues for CME
    • Previous Issues
    • TAM Policies and Practices
    • Permission Request Form
  • HIV Drug Resistance
    • HIV Drug Resistance Resources
    • HIV Drug Resistance Mutations Chart
    • Recent Webinars
    • Journal Articles
  • Fellow Resources
    • Resources for Fellows and Others New to the HIV Field
    • On-Demand Webinars for Fellows
    • IAS-USA Guidelines and Recommendations
    • On-Demand Webcasts
    • Research Collaborations
    • Additional Resources
  • About
    • Scientific Leadership Board
    • IAS-USA Leadership Award Recipients
    • Core Faculty
    • Mission
    • Staff
    • CME
    • Funding Information
    • Careers
    • Website Policies
    • Discrimination and Harassment Policy
    • Governance
    • Suggestions and Recommendations from San Francisco Locals
    • Donate
    • FAQs
Practice Question of the Week

October 12, 2026: Simplifying Antiretroviral Regimens in Virologically Suppressed Patients With Drug Resistance

You are caring for a patient who has a history of virologic failure with known nucleoside reverse transcriptase inhibitor (nRTI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance. He has most recently been on darunavir (DRV)/cobicistat (cobi)/tenofovir alafenamide (TAF)/emtricitabine (FTC) + dolutegravir (DTG) with good tolerance, adherence, and viral suppression. Although this regimen is only 2 pills per day, he is very interested in something even simpler and with smaller pills. You discuss a variety of options, including bictegravir (BIC)/lenacapavir (LEN). Which of the following statements regarding the ARTISTRY-1 (Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen) trial is TRUE?
Register for the Chicago Course
View Archived Questions
Leave Feedback
Subscribe